Evidence map›Paper›PMID 35283015›Full record

ArticleTrends in immunology2022

Odorant receptors in macrophages: potential targets for atherosclerosis.

Congcong Wang, Katrin I Andreasson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. TIM-4International journal of biological sciences · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Congcong WangDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Katrin I AndreassonDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA. Electronic address: kandreas@stanford.edu.
Stanford University · US

Funding

Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Jennifer Kaci Fairchild · 2020 to 2026
$29.0M
The role of TREM1 signaling in the development of Alzheimer’s diseaseRF1AG053001 · NIA · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2016 to 2016
$2.0M
Reprogramming myeloid cell metabolism to prevent cognitive aging and Alzheimer's DiseaseRF1AG070839 · NIA · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2021 to 2021
$1.9M
NIA NIH HHS P30 AG066515NIA NIH HHS RF1 AG053001NIA NIH HHS RF1 AG070839
6 · The paper itself

Abstract

In a recent report, Orecchioni et al. identify a role for the olfactory receptor (OR) Olfr2 and its human ortholog OR6A2 in atherosclerosis. Vascular macrophage Olfr2 binds octanal, a product of lipid peroxidation, activating the NLRP3 inflammasome and IL-1β secretion, and driving atherosclerosis pathology. Thus, OR6A2 inhibitors may represent a promising therapy for atherosclerosis.

Indexed as

AtherosclerosisReceptors, OdorantHumansInflammasomesMacrophagesNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinReceptors, Odorant

Identifiers

PMID35283015
PMCPMC10921635
OpenAlexW4220945214

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.